Published in
Oxford University Press, Journal of Antimicrobial Chemotherapy, 6(71), p. 1637-1642, 2016
DOI: 10.1093/jac/dkw031
Links
Tools
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial
Journal article published in 2016 by
Laura Galli,
Vincenzo Spagnuolo,
Alba Bigoloni,
Antonella D'Arminio Monforte,
Francesco Montella,
Andrea Antinori,
Antonio Di Biagio,
Stefano Rusconi 
,
Giovanni Guaraldi,
Simona Di Giambenedetto,
Marco Borderi,
Davide Gibellini,
Giada Caramatti,
Adriano Lazzarin,
Antonella Castagna
,
Giovanni Guaraldi,
Simona Di Giambenedetto,
Marco Borderi,
Davide Gibellini,
Giada Caramatti,
Adriano Lazzarin,
Antonella Castagna
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
To report the 96 week results on efficacy, safety and bone mineral density (BMD) in subjects with HIV-1 that were virologically suppressed and treated with atazanavir/ritonavir monotherapy versus atazanavir/ritonavir triple therapy.